The market for blood filtering device is expected to grow at a CAGR of around 4.3% from 2020 to 2027 and expected to reach the market value of around US$ 517.6 Mn by 2027.
Blood is composed of plasma solution and blood cells, where plasma solution contains several valuable proteins like immunoglobulin, factor VIII, factor IX, albumin, and vitronectin. Additionally, blood cells include erythrocytes, lymphocytes, monocytes, macrophages, neutrophils, basophils, eosinophils, megakaryocytes/platelets, and dendritic cells, and hematopoietic stem cells (HSCs). Blood needs to be filtered while transfusion in order to remove clots and small clumps of platelets and white blood cells that form during collection and storage. Naturally, the filtration of blood and other fluid is done by the kidneys in the human body. In a single day, kidneys filter about 150 quarts of blood. Artificially, blood filtration is performed by hemodialysis membranes, leukocyte removal filter, and plasma separation membranes
The increasing prevalence of diseases that require blood transfusions such as anemia, sickle cell disease, bleeding disorders like hemophilia, or cancer among others is propelling the market value. The increasing number of patients with chronic kidney diseases (CKD) is accelerating the demand for blood filtering devices in the market. CKD is commonly caused due to high blood pressure and doesn’t improve over time, it disables the normal functioning of the kidney and the condition requires performing dialysis that helps to filter and purify the blood with the help of an external machine. The global pandemic combined-19 is further bolstering the market value because the people with kidney disease, transplant recipients, and other severe chronic medical conditions are at high risk for developing coronavirus. As the people have weaker immune systems and it becomes harder for them to fight infections and it is important to continue with their regularly scheduled dialysis treatments. Additionally, the ongoing efforts to reduce the cost of procedures by the major players are projected to create potential opportunities over the estimated timeframe from 2020 to 2027.
On the other side, the risk and high cost associated with the procedure of blood transfusion are projected to limit the growth to an extent over the forecast period from 2020 to 2027.
The modern transfusion medicine transfuses the patients only with the required components, while in the traditional system whole blood collected was simply stored and transfused as it is to a patient. The new technique of blood processing is introduced, where if the patient is deficient in red cells only, then transfusion of other components including white cells, platelets, and plasma is not required and the component is used in other patients with the deficiency of the same. As a part of the process, whole blood is processed into various components and each component is stored under ideal storage condition (temperature, etc.) to ensure that the product is most effective when it is used. Additionally, special preservative solutions and blood bags are used to lengthen the expiry time and improve product quality.
North America accounted for the maximum revenue share in the market
In 2019, North America is leading the market with maximum revenue share owing to the increasing geriatric population and rising prevalence of chronic diseases. The major economies of the region including US and Canada are the major contributors to the regional market value. Around 13% of adults have CKD in US and the leading cause is diabetes and high blood pressure. Moreover, the US kidney failure cases comprises of 44% and 28% of diabetes and high blood pressure respectively in 2014. The primary reason for increasing diabetes rates is increasing obesity rates. Furthermore, in 2014 approx 430,000 Americans rely on regular blood-filtering dialysis treatments to survive with kidney failure. Furthermore, Asia Pacific is projected to exhibit the fastest growth with major CAGR (%) over the forecast timeframe from 2020 to 2027.
The players profiled in the report include Asahi Kasei Medical, BAINE, Braile Biomédica, Chengdu Shuanglu, GVS, Haemonetics, Infomed, Kaneka, KAWASUMI, Macopharma, Medtronic, Merck & Co., Inc., MITRA, Nanjing Celgene, Nanjing Shuangwei, Shandong Zhongbaokang, and Terumobct. The major blood filtering device players were involved in strategic developments for escalating the profit share in regional as well as the global market. The major investments were announced in the blood filtering device market for technological advancements in the field.
Market By Type
Leukocyte Removal Filter
Plasma Separation Membranes
Market By Applications
Market By End User
Ambulatory Surgical Centre
Market By Geography
Middle East & Africa
The market for blood filtering device is expected to reach a market value of around US$ 517.6 Mn by 2027.
The blood filtering device market is expected to grow at a CAGR of around 4.3% from 2020 to 2027.
The increasing prevalence of diseases that require blood transfusion, increasing number of patients with chronic kidney diseases (CKD), and global pandemic cobid-19 are some of the factors driving the market growth.
Asahi Kasei Medical, BAINE, Braile Biomédica, Chengdu Shuanglu, GVS, Haemonetics, Infomed, Kaneka, KAWASUMI, Macopharma, Medtronic, Merck & Co., Inc., MITRA, Nanjing Cellgene, Nanjing Shuangwei, Shandong Zhongbaokang, and Terumobct are the prominent players in the blood filtering device market.
North America held the highest market share in the blood filtering device market.
Asia Pacific is expected to be the fastest growing market over the forecast period.
In end use segment the Medical Centre segment is growing at faster pace.